Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Does interferon improve portal hypertension?

Diego Rincón1, Cristina Ripoll, María Vega Catalina

  • 1Hospital General Universitario Gregorio Marañón Dr Esquerdo 46, 28007, Madrid, Spain.

The Journal of Antimicrobial Chemotherapy
|May 25, 2006
PubMed
Summary

Antiviral therapy may improve liver disease in chronic hepatitis C patients, potentially reducing portal hypertension (PHT). Further research is needed to confirm these effects on liver fibrosis and PHT management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Steatotic Liver Disease at Primary Biliary Cholangitis Diagnosis: Association With Ursodeoxycholic Acid Response and Outcomes.

Liver international : official journal of the International Association for the Study of the Liver·2026
Same author

[Therapy-refractory hepatic encephalopathy or acquired hepato-cerebral degeneration - a challenging differential diagnosis].

Zeitschrift fur Gastroenterologie·2026
Same author

Treatment of Hypovitaminosis D Is Associated with Improvement in Anemia of Inflammation in Patients with Decompensated Cirrhosis.

Medical sciences (Basel, Switzerland)·2026
Same author

Clinical features and management for CDK4/6 inhibitor-DILI.

JHEP reports : innovation in hepatology·2026
Same author

De Novo Cancer in Liver Transplant Patients With Human Immunodeficiency Virus Infection: A Multicenter Nationwide Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2026
Same author

Prevalence of liver fibrosis in the general population (the LiverScreen project): a multinational European cohort study.

Lancet (London, England)·2026

Area of Science:

  • Hepatology
  • Gastroenterology
  • Virology

Background:

  • Chronic hepatitis C is a primary cause of advanced liver disease and cirrhosis globally.
  • Portal hypertension (PHT) is a common complication of cirrhosis, leading to severe outcomes and liver transplantation.
  • Antiviral therapy (AVT) shows potential benefits for liver inflammation and fibrosis, independent of viral clearance.

Purpose of the Study:

  • To review the impact of AVT on portal hypertension (PHT) in advanced chronic hepatitis C.
  • To explore the implications of AVT-induced histological changes on PHT.
  • To discuss clinical practice and future research directions regarding AVT and PHT.

Main Methods:

  • Literature review of studies investigating AVT in chronic hepatitis C patients with advanced liver disease.

Related Experiment Videos

  • Analysis of data on histological changes, liver inflammation, fibrosis, and portal hypertension.
  • Synthesis of findings on the relationship between AVT, histological improvements, and PHT.

    • Main Results:

    • AVT may exert beneficial effects on liver histology, including inflammation and fibrosis.
    • The influence of these histological changes on portal hypertension (PHT) is under investigation.
    • Evidence suggests a potential, albeit not fully elucidated, impact of AVT on PHT.

    Conclusions:

    • AVT may offer benefits beyond viral eradication, potentially impacting PHT in chronic hepatitis C.
    • Further research is crucial to understand the mechanisms and clinical significance of AVT's effect on PHT.
    • Investigating AVT's role in managing PHT could refine treatment strategies for advanced liver disease.